```html

Pfizer Research Grant – Pre-clinical Investigation of anti-TFPI-mediated Rebalancing Mechanisms in Non-Hemophilic Bleeding Disorders supports investigator-initiated preclinical and foundational research exploring the therapeutic potential of Tissue Factor Pathway Inhibitor (TFPI) modulation in inherited and non-hemophilic bleeding disorders. This competitive grant program, managed through Pfizer’s internal review process, seeks to address the scientific gap in understanding how anti-TFPI-mediated hemostatic rebalancing may benefit patients with bleeding conditions other than hemophilia.

Overview

The programme invites proposals focused on generating preclinical and basic science data that examine the mechanisms of TFPI modulation or rebalancing in bleeding disorders outside of hemophilia. Projects should aim to clarify how TFPI inhibition may restore hemostatic function in conditions that share impaired thrombin generation as a common functional endpoint. Applications from eligible institutions in Brazil, China, Europe, Israel, Japan, Saudi Arabia, South Korea, Turkey, and the United States are accepted.

Research Areas and Activities

Proposals should address one or more of the following areas of interest:

• Rare bleeding disorders arising from deficiencies in clotting factors or pathway components that converge on impaired thrombin generation, including Factor II, Factor V, Factor VII, Factor X, and Factor XI deficiencies, as well as von Willebrand disease.
• Glanzmann’s thrombasthenia (GT), a disorder of platelet aggregation due to GPIIb/IIIa dysfunction with generally preserved thrombin generation, which presents a distinct pathophysiological mechanism.
• Bleeding disorder of unknown cause (BDUC), defined as a diagnostic category encompassing patients with an abnormal bleeding tendency yet normal hemostatic evaluation.

Note: Proposals related to hemophilia A (FVIII deficiencies) and hemophilia B (FIX deficiencies) are outside the scope of this request for proposals.

Funding and Benefits

• Maximum project request: Up to $50,000 USD per individual project.
• Study drug costs: Pfizer will cover the product for the study at a maximum cost of $50,000 USD per project, in addition to the project costs.
• Total combined limit: Project costs and study drug costs must not exceed $100,000 USD.
• Total available budget: Approximately $300,000 USD for this RFP.
• Maximum project length: 1 year.
• Overhead: Institutional overhead costs are capped at 28% per Pfizer policy. Award amounts include direct costs, indirect costs, and institutional overhead.
• Eligible expenses: Study-specific costs may be included; capital purchases (equipment, software licenses, technology, bricks and mortar) are not funded. Equipment hire or leasing is acceptable.

Eligibility

• Geographic scope: Institutions and Principal Investigators must be based in Brazil, China, Europe, Israel, Japan, Saudi Arabia, South Korea, Turkey, or the United States.
• Organization requirement: Only organizations are eligible to receive grants. Individuals or independent medical practice groups not affiliated with a hospital, academic institution, or professional society are not eligible.
• Principal Investigator qualifications: The PI must hold a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
• Employment status: The PI must be an employee or contractor of the requesting organization.
• Legal capacity: The requesting organization must be legally able to receive award funding directly from Pfizer Inc. Applicants are strongly advised to confirm this prior to submission.
• Multi-institution projects: If the project involves multiple departments or institutions, all parties must have a relevant role, and the requesting organization must hold a key role.

Application Process

Applications must be submitted through the online portal at www.cybergrants.com/pfizer/Research. First-time users should create a password before starting. In the application, select “Yes” for the Competitive Grant question, choose the Primary Area of Interest “Non-Hemophilia Bleeding Disorders – RES”, and select the Competitive Grant Program Name “2026 RD G Rare Bleeding TFPI Mechanisms RES”.

Proposals must be uploaded in the Proposal/Protocol field and should be single-spaced using Calibri 12-point font with 1-inch margins. The full proposal is limited to 15 pages excluding references and should address: goals and objectives, assessment of need, target audience, project design and methods, innovation, evaluation and outcomes, anticipated project timeline, additional information, organization details, and a budget detail in U.S. dollars.

Required documents include the project plan or proposal, initial study protocol, and IRB approval (or proof of submission). IRB approval is not mandatory at the time of submission but must be in place prior to 1 December 2026.

Deadline and Timeline

• RFP release date: 12 May 2026
• Submission deadline: 1 July 2026, 23:59 Eastern Standard Time (New York, GMT-5). Applications submitted after the due date will not be reviewed.
• Anticipated grant award notification: 8 October 2026
• Anticipated project start date: 1 January 2027
• Anticipated project end date: 31 December 2027

Questions regarding this RFP should be directed in writing to the Grant Officer, Talita Honorato-Rzeszewicz, at talita.honorato-rzeszewicz@pfizer.com with the subject line “2026 RD G Rare Bleeding TFPI Mechanisms RES”. Technical difficulties with the submission website should be reported through the Cybergrants platform.

```